Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751549 | 0.86 | HDAC1 (0.47) | ALDH1A1LMNAPOLBMAPTKDM4E | |
| SCHEMBL1414421 | 0.86 | KLKB1 (0.50) | SMN1; SMN2KLKB1KLK1RIPK1 | |
| SCHEMBL13529256 | 0.83 | MAPT (0.48) | ALDH1A1LMNASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL23081358 | 0.82 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2POLBMAPK1RIPK1 | |
| SCHEMBL24310893 | 0.81 | KLKB1 (0.48) | ALDH1A1KLKB1KLK1RIPK1 | |
| SCHEMBL19658305 | 0.81 | KLKB1 (0.50) | ALDH1A1LMNASMN1; SMN2KLKB1TSHR | |
| SCHEMBL22040159 | 0.81 | JMJD6 (0.45) | ALDH1A1SMN1; SMN2TSHRMAPT | |
| SCHEMBL1414358 | 0.81 | KLKB1 (0.49) | KLKB1TSHRCYP19A1KLK1RIPK1 | |
| SCHEMBL6855286 | 0.79 | KMT2A (0.40) | ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL20095692 | 0.79 | KLKB1 (0.47) | ALDH1A1KLKB1KLK1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384510-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | ;Eli Lilly and Company (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3788045-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3788045-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112384510-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2019-11-07 | — | — | US | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ALDH1A1 4521/4885LMNA 1214/4885SMN1; SMN2 1818/4885 |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALDH1A1 4521/4885LMNA 1214/4885SMN1; SMN2 1818/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALDH1A1 4521/4885LMNA 1214/4885SMN1; SMN2 1818/4885 |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALDH1A1 4521/4885LMNA 1214/4885SMN1; SMN2 1818/4885 |
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | ALDH1A1 1556/4885LMNA 4708/4885SMN1; SMN2 3584/4885 |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ALDH1A1 4521/4885LMNA 1214/4885SMN1; SMN2 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.